Syndrome hémolytique et urémique

Hemolytic uremic syndrome is formally characterized as a clinical syndrome marked by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury ^[1][2]. The disorder encompasses distinct pathogenic pathways, broadly stratified into Shiga toxin-associated variants resulting from specific bacterial gastrointestinal infections and atypical forms linked to genetic mutations or acquired autoantibodies targeting complement regulators ^[3][1]. Both etiologies ultimately converge on widespread endothelial injury and the formation of microvascular thrombi, leading to multi-organ system dysfunction ^[3][2].

Initial manifestations typically commence with gastrointestinal distress, including bloody diarrhea, abdominal cramping, mild fever, and vomiting, which generally appear three to ten days following exposure to contaminated sources ^[2]. Renal compromise and cytopenias typically emerge five to ten days after symptom onset, coinciding with the natural resolution of the diarrheal illness ^[2]. While the syndrome predominantly affects children, older adults and elderly patients frequently experience more complex presentations involving neurological deficits, cardiovascular strain, and prolonged organ dysfunction ^[2]. Long-term sequelae can include persistent hypertension, seizure disorders, visual impairment, and chronic renal insufficiency in a subset of survivors ^[2].

The annual incidence of hemolytic uremic syndrome is estimated at approximately 1.5 cases per 100,000 individuals across affected populations ^[2]. Pediatric cohorts bear the highest disease burden, whereas adult presentations frequently demonstrate more severe systemic involvement ^[2]. Age significantly influences acute mortality, with fatality rates hovering around 3% in young children but rising to approximately 20% among middle-aged and older adults ^[2]. Longitudinal tracking indicates that roughly one-third of survivors may exhibit persistent renal abnormalities, while less than 10% progress to end-stage kidney disease requiring sustained dialysis ^[2].

1. 1 Boyer O et al. Hemolytic-Uremic Syndrome in Children. Pediatr Clin North Am. 2022 Dec. PMID: 36880929. doi: 10.1016/j.pcl.2022.07.006. PubMed: https://pubmed.ncbi.nlm.nih.gov/36880929/
2. 2 Wikipedia contributors. Hemolytic–uremic syndrome - Wikipedia [Internet]. Wikipedia. cited 2 Sept 2026. Available from: https://en.wikipedia.org/wiki/Hemolytic%E2%80%93uremic_syndrome
3. 3 Raina R et al. Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment. Ther Apher Dial. 2019 Feb. PMID: 30294946. doi: 10.1111/1744-9987.12763. PubMed: https://pubmed.ncbi.nlm.nih.gov/30294946/
4. 4 Abou-Ismail MY et al. Thrombotic microangiopathies: An illustrated review. Res Pract Thromb Haemost. 2022 Mar. PMID: 35615754. doi: 10.1002/rth2.12708. PubMed: https://pubmed.ncbi.nlm.nih.gov/35615754/